Federation Des Caisses Desjardins Du Quebec Bellus Health Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2024	SELL	$0.0 - $14.75 $0 - $42,686	-2,894 Closed	0 $0
Q1 2023 Aug 14, 2024	SELL	$7.14 - $8.53 $12,145 - $14,509	-1,701 Reduced 37.02%	2,894 $20.5 Million
Q4 2022 Aug 14, 2024	SELL	$8.22 - $10.76 $452 - $591	-55 Reduced 1.18%	4,595 $37.6 Million
Q3 2022 Aug 14, 2024	SELL	$8.95 - $12.0 $15,572 - $20,880	-1,740 Reduced 27.23%	4,650 $49.2 Million
Q2 2022 Aug 14, 2024	SELL	$6.46 - $10.02 $45,866 - $71,142	-7,100 Reduced 52.63%	6,390 $58.3 Million
Q1 2022 Aug 14, 2024	BUY	$5.56 - $7.99 $75,004 - $107,785	13,490 New	13,490 $91.9 Million
Q4 2021 Aug 30, 2024	BUY	$5.26 - $8.3 $161,150 - $254,287	30,637 Added 208.36%	45,341 $359 Million
Q3 2021 Aug 30, 2024	SELL	$2.7 - $6.64 $21,386 - $52,595	-7,921 Reduced 35.01%	14,704 $87.6 Million
Q2 2021 Aug 30, 2024	BUY	$3.11 - $4.61 $70,363 - $104,301	22,625 New	22,625 $70 Million
Q1 2021 Aug 30, 2024	SELL	$3.03 - $4.58 $10,302 - $15,572	-3,400 Reduced 24.73%	10,348 $39.4 Million
Q4 2020 Aug 30, 2024	BUY	$2.27 - $3.3 $3,684 - $5,355	1,623 Added 13.39%	13,748 $41.3 Million
Q3 2020 Aug 30, 2024	SELL	$2.14 - $12.02 $4,708 - $26,444	-2,200 Reduced 15.36%	12,125 $27.2 Million
Q2 2020 Aug 30, 2024	SELL	$8.88 - $11.15 $8,320 - $10,447	-937 Reduced 6.14%	14,325 $146 Million
Q1 2020 Aug 30, 2024	SELL	$5.77 - $10.85 $17,777 - $33,428	-3,081 Reduced 16.8%	15,262 $150 Million
Q4 2019 Aug 30, 2024	SELL	$5.76 - $7.6 $927 - $1,223	-161 Reduced 0.87%	18,343 $138 Million
Q3 2019 Aug 30, 2024	BUY	$6.24 - $8.84 $115,464 - $163,575	18,504 New	18,504 $116 Million

Others Institutions Holding BLU

# of Institutions

Shares Held

128K

Call Options Held

Put Options Held

Pendal Group LTD

128K
Shares

$0
0.01% of portfolio

View Full List

About BELLUS Health Inc.

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

More about BLU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account